Documenting adherence to psychostimulants in children with ADHD


This study evaluates the validity, inter-rater reliability, and stability over 3 months of a semi-structured telephone interview measuring adherence to stimulant treatment, the Stimulant Adherence Measure, against the Medication Event Monitoring System (MEMS).
Clinic-referred children (N=22, age 11.85 +/- 2.1 yrs) using psychostimulants for DSM-IV attention-deficit/hyperactivity disorder (ADHD) were eligible. Families used a MEMS device for the primary stimulant medication. Children and parents participated in a semi-structured telephone interview, the Stimulant Adherence Measure, for 3 consecutive months. Parent reports for previous 7 days and 28 days and child report for previous 7 days of medication use were compared to MEMS report. Inter-rater reliability and interview order were also examined.
Nineteen children and parents completed (86%). Agreement between MEMS and parent report for previous 7 days at months 1, 2 and 3 (ICC=0.829, p<0.001; ICC=0.663, p<0.05; ICC=0.878, p<0.001 respectively) and for 28 days at months 1, 2 and 3 (ICC=0.793, p<0.001; ICC=0.907, p< 0.001; ICC=0.806, p<0.001 respectively) was good to excellent. Agreement between MEMS and child report for 7 days at months 1, 2 and 3 (ICC=0.773, p<0.001, ICC=0.542, p<0.05, ICC=0.606, p<0.05 respectively) was good. Inter-rater reliability was excellent (ICC=0.956, p<0.001). There was no interview order effect for parents (F=1.771, p>0.05) or children (F=1.621, p>0.05).
The Stimulant Adherence Measure provides a valid and reliable method for determining stimulant medication use by children with ADHD.

Download full-text


Available from: Amy Gajaria, Aug 17, 2015
  • Source
    • "The Medication Event Monitoring System (MEMS; Aardex Ltd., Union City, CA, USA) is a device that records the date and time the pill container was opened using an electronic computer chip implanted into the cap of a prescription bottle. Data are downloaded directly into a computer program.15 This tool reliably assesses medication use in clinical and research settings and is regarded as the gold standard for evaluating adherence.16 "
    [Show abstract] [Hide abstract]
    ABSTRACT: The primary aim of this study was to compare electronic monitoring with other measures of adherence to Osmotic-controlled Release Oral delivery System methylphenidate in children with attention-deficit hyperactivity disorder (ADHD). The secondary aim was to analyze the relationships between adherence and clinical factors, including ADHD symptoms. Thirty-nine children diagnosed with ADHD were monitored for adherence to medication over the course of eight weeks. Medication adherence was assessed using the Medication Event Monitoring System (MEMS), which is a bottle cap with a microprocessor that records all instances and times that the bottle is opened; patient self-report; clinician rating; and pill count. Information, including demographic and clinical characteristics, symptom rating scale, and psychological test results, were also collected. The relationships between adherence and clinical factors, including ADHD rating scores of baseline and of the changes, were assessed. The rate of non-adherence measured by the MEMS was found to be 46.2%, which was considerably higher than those of the patient self-report (17.9%), clinician rating (31.7%), and pill count (12.8%) of non-adherence. The rate of adherence measured by the MEMS was not significantly associated with baseline symptom severity or symptom changes over the eight weeks, although non-adherent group showed more severe baseline symptoms and inferior improvement. Adherence as measured by the MEMS showed a discrepancy with other measures of adherence in patients with ADHD. The symptom severity and level of improvement were not related to adherence with MEMS. Further studies are needed to evaluate the variables that may impact medication adherence in children with ADHD.
    Psychiatry investigation 09/2012; 9(3):263-8. DOI:10.4306/pi.2012.9.3.263 · 1.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Attention-deficit/hyperactivity disorder (ADHD) is a common psychiatric disorder of childhood, characterized by excessive inattention, hyperactivity and impulsivity. Effective medication exists for the condition, yet suboptimal long-term effects persist for children with ADHD. Poor adherence is a common issue for individuals with chronic conditions, including children and those with psychiatric conditions, and ADHD is no exception. This review examines the available evidence regarding patterns of long-term use of stimulant medication and the predictors of medication discontinuation among children with ADHD, and suggests future clinical and research directions for improving adherence in children with ADHD.
    Expert Review of Neurotherapeutics 11/2008; 8(10):1563-71. DOI:10.1586/14737175.8.10.1563 · 2.78 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Pharmacotherapy plays a primary role in the management of attention-deficit/hyperactivity disorder (ADHD), despite the availability of effective behavioral interventions. Psychostimulants are the most commonly prescribed form of pharmacotherapy for patients with ADHD and their benefits in managed care are severalfold, leading not only to symptom resolution and improved quality of life for patients, but also reduced costs for payers and purchasers. The use of these agents requires careful consideration and management by health plan stakeholders for optimal effectiveness. Concerns regarding medication adherence, in addition to the potential for diversion and abuse of psychostimulants, highlight the importance of effective pharmacotherapy management in patients with ADHD. Initiatives promoting medication adherence, such as patient/parent education, provider follow-up, and adverse effect management, are crucial for ensuring treatment success. Once-daily, extended-release formulations of stimulants may also contribute to improving medication adherence, as may managed care pharmacy interventions such as pharmacy database monitoring.
    The American journal of managed care 06/2009; 15(5 Suppl):S141-50. · 2.26 Impact Factor
Show more